September 27, 2024 Conceptualizing meaningful between-group difference in change over time: a demonstration of possible viewpoints Purpose Determining if group-level differences in health outcomes are meaningful has recently been neglected...
September 26, 2024-September 27, 2024 2024 Complex In Vitro Model: Qualification Framework Public Workshop Critical Path Institute’s (C-Path) Predictive Safety Testing Consortium (PSTC) is delighted to announce the second...
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
September 12, 2024 C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development C-Path successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024.
September 12, 2024 Steve Gleason Welcomes Guests to Day 2 of #CGIC24 Former NFL player and ALS patient advocate welcomes attendees to the second day of C-Path’s Global Impact Conference.
September 9, 2024-September 11, 2024 C-Path Hosts its Inaugural Global Impact Conference We are thrilled to invite you to the inaugural Critical Path Institute Global Impact Conference taking place this September...
September 9, 2024 FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker...
September 5, 2024 Cystic Fibrosis Therapeutics Development Network Contributes New Data Sets to C-Path’s RDCA-DAP, Advancing CF Research and Treatment Strategies Critical Path Institute (C-Path) today announced the addition of significant new data sets...
August 29, 2024 ASN 2024 Poster: EL-PFDD v SONG: PKDOC, the PKD Foundation, and the ARPKD community hosted an Externally-led Patient Focused Drug Development (EL-PFDD) meeting...
August 22, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer C-Path proudly announced today a $250,000 grant award to Peter Wipf, Ph.D...